Scottish Investment Bank

Green Bioactives is a sustainable biomanufacturing company that uses plant cell culture technology to produce plant-derived biomolecules. By cultivating vascular stem cells, it creates rare botanical compounds with higher effectiveness, durability, and environmental benefits, providing industries with reliable, scalable, and eco-friendly sources of natural materials.

Lentitek is a cell and gene therapy company developing gene therapies and gene-modified cell therapies to broaden access to cures. It focuses on increasing the production yields of lentiviral vectors through its platform, using a novel promoter and proprietary production methods. The approach aims to deliver substantially higher yields, potentially reducing manufacturing costs and improving scalability for healthcare providers delivering gene therapies.

uFraction8 specializes in scalable bioprocessing technology for efficient biomass filtration, separation, and dewatering. Its innovative method is applicable to various microbes like microalgae, yeast, and bacteria, offering a harm-free and flocculant-free alternative to traditional centrifuges, filters, and membranes.

Dyneval specializes in developing portable technology for analyzing cattle semen dynamics at the nano- and micro-scale. Its equipment enables accurate characterization of particles and microorganisms, enhancing reliability in health and biotech sectors.

Concinnity Genetics specializes in enhancing the safety of gene therapies. It employs an artificial intelligence platform to engineer innovative control mechanisms, making gene therapies more predictable, controllable, and safe. This enables researchers to swiftly design and optimize gene therapies for diverse applications.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

Neuranics develops magnetic sensing technology for integration into health, fitness, and metaverse applications. Its proprietary spintronics sensors, powered by semiconductors, detect tiny magnetic impulses from the body, aiming to improve health monitoring equipment and human-machine interfaces.

ILC Therapeutics is a biotechnology company developing novel peptide therapeutics to modulate the innate immune system. Its focus includes treating cancer, atopic dermatitis, psoriasis, and more recently, COVID-19.

Metacarpal develops body-powered bionic hand prostheses, including a fully mechanical design with variable grips and grip lock to secure holds. The technology provides intuitive control similar to traditional body-powered devices and offers multiple grip options to adapt to different objects, with a focus on expanding access to prosthetic solutions in developing regions.

Mirna is a veterinary diagnostics company that specializes in the development of veterinary disease testing technology.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Nebu-Flow is a manufacturer focused on the development of advanced inhaled drugs aimed at patients with respiratory disorders. The company specializes in innovative pulmonary drug-delivery technology that allows for efficient administration of difficult-to-nebulize medications directly to the lungs. This includes existing formulations as well as emerging therapeutics such as biologics, nanomedicines, and vaccines. Nebu-Flow's technology is designed to control droplet size for optimal deep lung deposition, facilitating injection-free systemic drug delivery through inhalation. The company is dedicated to minimizing its environmental impact while ensuring the creation of a user-friendly and high-performing nebulizer for effective treatment of respiratory diseases.

Glen Clova Scientific is focused on developing a new generation of active biological drugs that aim to form natural antibodies against harmful targets. The company's innovative approach enhances the quality of treatment for chronic diseases by minimizing the need for safety monitoring and reducing the frequency of dosing. This not only helps to lower the overall cost of treatment for patients but also expands access to healthcare in markets with limited infrastructure. Through its advancements in biologic drug development, Glen Clova Scientific seeks to improve patient outcomes and provide effective therapeutic options.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Intelligent Growth Solutions Ltd is a company that specializes in developing and providing advanced vertical farming technology for indoor food production. Founded in 2013 and based in Dundee, United Kingdom, the company offers a plug-and-play solution that includes an indoor vertical farming demonstration facility. This facility features an Internet of Things (IoT)-enabled power and communications platform, incorporating patented electrical, electronic, and mechanical technologies. Intelligent Growth Solutions is committed to creating optimal growing environments for plants and enhancing user experience through continuous innovation and effective design.

Glox Therapeutics specializes in developing precision antibiotic therapies derived from naturally occurring bacteriocins. Their focus is on targeting and eliminating specific, hard-to-treat gram-negative bacterial pathogens that are resistant to traditional antibiotics. By preserving the patient's microbiome, their approach aims to minimize side effects and provide a more balanced treatment strategy, thereby advancing the field of antimicrobial therapy.

Beta Bugs specializes in insect genetics, developing high-performance Black Soldier Fly breeds for insect farmers. Headquartered at Easter Bush Campus, it collaborates with the Roslin Institute to enhance productivity in the insect protein sector.

Microplate Dx develops innovative diagnostic technology aimed at reducing fatalities caused by drug-resistant infections. The company, spun out from the University of Strathclyde in Glasgow, focuses on creating point-of-care solutions that accurately detect specific infections and enable optimal antibiotic prescribing within an hour.

ENOUGH is a company that develops and commercializes patented technology for producing mycoprotein, a meat-free food product. Its innovative process integrates production within existing bio-refineries, creating a sustainable and efficient system that produces Food, Fuel, and Feed simultaneously.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

Carbogenics is a UK-based company that develops and produces sustainable agricultural and waste-to-resource technologies. It focuses on turning disposable coffee cups and other non-recyclable paper waste into value-added products, including carbon-rich materials that stimulate biogas production and improve plant growth, and it offers CreChar as a carbon additive. The company provides plant fertilizer products and consultancy and analytical services for anaerobic digestion facilities, supporting operators in wastewater and biogas applications. Its low-carbon technology converts difficult-to-recycle organic waste into carbon adsorbents used to boost digestion performance and agricultural yields. Founded in 2016 and based in Edinburgh, Carbogenics aims to create circular economy solutions by transforming waste streams into fertilizers, soil amendments, and bio-additives for farming and digestion processes.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Founded in 2008, Manus Neurodynamica specializes in medical diagnostic technologies for neuromotor impairments. Its primary product is a non-invasive device designed to support early diagnostics and monitoring of Parkinson's disease, with applications in academic research, pharmaceutical studies, and non-medical uses.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, dedicated to developing novel microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its key products include EquiMiR, a treatment for equine tendinopathy that mimics natural microRNA with enhanced pharmacological properties, and TenoMiR, which restores critical microRNA levels to improve tendon strength and facilitate recovery. By targeting the molecular mechanisms underlying tendon damage and tendinopathy, Causeway Therapeutics aims to provide advanced therapeutic solutions that alleviate pain and promote faster healing for patients suffering from musculoskeletal diseases.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Green Bioactives is a sustainable biomanufacturing company that uses plant cell culture technology to produce plant-derived biomolecules. By cultivating vascular stem cells, it creates rare botanical compounds with higher effectiveness, durability, and environmental benefits, providing industries with reliable, scalable, and eco-friendly sources of natural materials.

Cytomos Limited, established in 2011 and based in Edinburgh, United Kingdom, specializes in developing advanced cell sorting devices for laboratory research and clinical diagnostics. The company is known for its patented Dielectric Spectroscopy (CDS) technology, which enables label-free cell analysis with single-cell resolution. This innovative approach provides comprehensive insights into bioprocesses, facilitating automated and quantitative assessments crucial for biomedical research. Cytomos' systems are designed to support biopharma and cell therapy applications by offering deep data analysis per cell, thereby enhancing phenotypic drug discovery and stem cell therapy. By leveraging machine learning algorithms, Cytomos provides researchers with the tools necessary to optimize cell-based diagnostics and ensure accurate dosing in therapeutic contexts.

BioCaptiva develops innovative liquid biopsy technology devices aimed at diagnosing and monitoring hard-to-detect cancers. Its proprietary platform captures circulating free DNA from blood samples, overcoming current limitations of cancer liquid biopsy testing.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

ŌGI Bio is a start-up company emerging from The University of Edinburgh, focused on transforming microbial cultivation and management. The company has developed a modular culturing system that aims to replicate traditional manual flask culturing methods. This innovative system consists of a base unit, which can be customized with retrofittable modules that allow users to add or remove features according to their specific measurement and control needs during the culturing process. By offering this flexible approach, ŌGI Bio seeks to enhance the efficiency and effectiveness of microbial research and applications.

Carcinotech is a pioneering company in cancer research, specializing in the manufacturing of 3D-printed micro-tumors derived from patient biopsies, primary cells, immune cells, and cancer stem cells. The company aims to enhance the drug screening process and facilitate pre-clinical and personalized medicine testing, ultimately accelerating the delivery of more effective cancer treatments to market. By employing advanced techniques in tissue engineering, robotic manufacturing, and stringent quality control, Carcinotech produces highly predictive, assay-ready printed tumors that reflect the heterogeneity of individual cancers. This innovative approach provides clinicians with models of "clinical biopsy" quality, significantly improving the accuracy of cancer treatment assessments. Collaborating with global partners, including leading pharmaceutical companies and medical professionals, Carcinotech is committed to transforming oncology drug development and increasing the likelihood of successful outcomes for cancer patients.

Kynos Therapeutics develops novel therapies targeting Kaiser-Meyer-Olkin (KMO), a key enzyme involved in inflammation, immunity, and metabolism. Its focus is on indications with unmet medical needs.

Axol Bioscience Ltd., established in 2012 and based in Little Chesterford, United Kingdom, specializes in human cell culture systems for research purposes. The company produces and supplies various types of human cells derived from induced pluripotent stem cells (iPSCs), such as cardiomyocytes, neural stem cells, and astrocytes, along with primary cells like endothelial cells and fibroblasts. Axol also provides essential media, reagents, and growth factors to maintain these cell cultures. Additionally, they offer custom services including iPSC reprogramming, differentiation, genome editing, and cell sourcing tailored to clients' needs. Their products are distributed globally through strategic partners in various countries across Asia, North America, Europe, and internationally.

Rhizocore Technologies specializes in producing locally-adapted mycorrhizal fungi to enhance tree planting success. Its platform aims to boost woodland restoration, commercial productivity, and environmental stress tolerance within the forestry market.

Founded in 2021 by Brian Quinn, WellFish Tech specializes in enhancing aquaculture sustainability through innovative fish health monitoring. Utilizing rapid, non-lethal blood analysis, the company aims to improve productivity and profitability for marine net pen operators.

Cumulus Oncology Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative anti-cancer therapies for clinical settings characterized by high unmet medical needs. Established in 2017, the company targets critical pathways in cancer treatment to enhance the efficacy and outcomes of existing and experimental therapies. Cumulus Oncology's lead candidate is a preclinical oral Chk1 kinase inhibitor designed to facilitate DNA repair, thereby improving treatment effectiveness for cancer patients. The company is supported by a team of seasoned professionals and industry partners with extensive experience in drug discovery and development, providing valuable insights into optimal cancer treatment strategies.

Valneva is a vaccine company focused on developing prophylactic vaccines for infectious diseases with significant unmet medical needs. It has successfully commercialized two vaccines, IXIARO/JESPECT and DUKORAL, and is advancing candidates against Lyme disease, chikungunya virus, and COVID-19.

uFraction8 specializes in scalable bioprocessing technology for efficient biomass filtration, separation, and dewatering. Its innovative method is applicable to various microbes like microalgae, yeast, and bacteria, offering a harm-free and flocculant-free alternative to traditional centrifuges, filters, and membranes.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Cytochroma manufacture genetically diverse stem cell-derived models to predict the safety and effect of drugs in a global population. Cytochroma’s automated cell manufacture, physiologically relevant models and rapid screening platform makes preclinical testing faster, safer and smarter.

Dyneval specializes in developing portable technology for analyzing cattle semen dynamics at the nano- and micro-scale. Its equipment enables accurate characterization of particles and microorganisms, enhancing reliability in health and biotech sectors.

Intelligent Growth Solutions Ltd is a company that specializes in developing and providing advanced vertical farming technology for indoor food production. Founded in 2013 and based in Dundee, United Kingdom, the company offers a plug-and-play solution that includes an indoor vertical farming demonstration facility. This facility features an Internet of Things (IoT)-enabled power and communications platform, incorporating patented electrical, electronic, and mechanical technologies. Intelligent Growth Solutions is committed to creating optimal growing environments for plants and enhancing user experience through continuous innovation and effective design.

Tay Therapeutics is a biotechnology company focused on drug discovery for the treatment of inflammatory conditions, particularly skin diseases. The company is dedicated to developing innovative topical and oral therapies that serve as alternatives to traditional steroid creams, which are commonly prescribed for conditions like psoriasis and eczema. Recognizing the limitations and potential side effects associated with steroid treatments, Tay Therapeutics aims to deliver safe and effective medications that improve patient outcomes. By prioritizing the needs of patients suffering from skin diseases, the company seeks to revolutionize the therapeutic landscape in this area.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Macomics is an immuno-oncology company focused on developing immunotherapies that modulate macrophages to reprogram the tumor microenvironment and boost the body's immune response against cancer. The company pursues novel, first-in-class therapies designed to overcome macrophage-driven immunosuppression, enabling broader clinical benefits for patients. Based in Edinburgh, United Kingdom, it develops precision medicines that target macrophage biology to enhance anticancer immunity.

ENOUGH is a company that develops and commercializes patented technology for producing mycoprotein, a meat-free food product. Its innovative process integrates production within existing bio-refineries, creating a sustainable and efficient system that produces Food, Fuel, and Feed simultaneously.

ILC Therapeutics is a biotechnology company developing novel peptide therapeutics to modulate the innate immune system. Its focus includes treating cancer, atopic dermatitis, psoriasis, and more recently, COVID-19.

BioCaptiva develops innovative liquid biopsy technology devices aimed at diagnosing and monitoring hard-to-detect cancers. Its proprietary platform captures circulating free DNA from blood samples, overcoming current limitations of cancer liquid biopsy testing.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Asklepios BioPharmaceutical is a biotechnology company focused on developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It employs proprietary AAV technology and a manufacturing platform to advance a diverse pipeline that includes in-house clinical programs in Pompe disease and congestive heart failure, as well as preclinical programs spanning neuromuscular and central nervous system conditions. The company also collaborates and out-licenses clinical indications such as hemophilia and Duchenne muscular dystrophy, supported by capabilities in scalable cell-line manufacturing and an extensive AAV capsid and promoter library. Founded in 2001 and based in Research Triangle Park, North Carolina, the company seeks to advance genetic medicines through collaborations, new delivery methods, and ongoing pipeline expansion.

Macomics is an immuno-oncology company focused on developing immunotherapies that modulate macrophages to reprogram the tumor microenvironment and boost the body's immune response against cancer. The company pursues novel, first-in-class therapies designed to overcome macrophage-driven immunosuppression, enabling broader clinical benefits for patients. Based in Edinburgh, United Kingdom, it develops precision medicines that target macrophage biology to enhance anticancer immunity.

Founded in 2008, Manus Neurodynamica specializes in medical diagnostic technologies for neuromotor impairments. Its primary product is a non-invasive device designed to support early diagnostics and monitoring of Parkinson's disease, with applications in academic research, pharmaceutical studies, and non-medical uses.

Founded in 2016 and spun out from the University of St Andrews, Pneumagen focuses on developing glycan-targeted carbohydrate-binding modules (CBMs) for treating respiratory tract infections and cancer.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Founded in 2017, Amphista Therapeutics is a biopharmaceutical company based in Motherwell, UK. It specializes in developing first-in-class cancer therapeutics using targeted protein degradation technology to selectively remove disease-causing proteins.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Wobble Genomics specializes in maximizing RNA and DNA sequencing efficiency for the discovery and detection of nucleic acid biomarkers.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Founded in 2009, MedAnnex is a UK-based biotechnology company dedicated to developing first-in-class antibody therapies for treating cancers and autoimmune diseases. Its lead product, annexuzlimab, targets annexin-A1 to inhibit cancer cell growth and autoimmune condition development.

CuanTec Ltd is a Scottish biotechnology company based in Motherwell, United Kingdom, founded in 2016. The company specializes in manufacturing biodegradable and compostable plastic films specifically for the food industry, using an innovative process that extracts chitin from the waste of shellfish, particularly langoustines. By utilizing a circular economy approach, CuanTec transforms marine waste from the fisheries industry into environmentally responsible packaging solutions. Their production process is low-energy and minimizes waste, employing harmless bacteria to extract chitin, resulting in a high-quality product. CuanTec's films are not only antimicrobial but also compostable and biodegradable, addressing the pressing issue of plastic pollution and helping to extend the shelf life of fresh food while reducing food waste.

MGB Biopharma is a UK-based biopharmaceutical company developing novel anti-infective medicines. It focuses on small molecules with specific antibacterial effects, targeting resistant bacteria using its proprietary DNA Minor Groove Binders technology.

Censo Biotechnologies Ltd is a stem cell technology company specializing in the provision of human cells and contract research services aimed at drug discovery, toxicity testing, and cell banking. Utilizing its induced pluripotent stem cells (iPSCs) technology, Censo generates stem cells from skin or blood samples provided by donors. The company's offerings include human tissue sample procurement, iPSC generation, genome editing, differentiated cell protocol development, and the production of specific differentiated cell lineages. Censo focuses on supporting research related to neurodegenerative and neuro-inflammatory diseases by providing gene editing capabilities using CRISPR technology and a diverse range of existing human iPSC lines. Founded in 2008 and headquartered in Edinburgh, with an additional office in Cambridge, Censo aims to facilitate advancements in biotechnology through its innovative services.

Intelligent Growth Solutions Ltd is a company that specializes in developing and providing advanced vertical farming technology for indoor food production. Founded in 2013 and based in Dundee, United Kingdom, the company offers a plug-and-play solution that includes an indoor vertical farming demonstration facility. This facility features an Internet of Things (IoT)-enabled power and communications platform, incorporating patented electrical, electronic, and mechanical technologies. Intelligent Growth Solutions is committed to creating optimal growing environments for plants and enhancing user experience through continuous innovation and effective design.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Dxcover is a clinical-stage liquid biopsy company based in Glasgow, established in 2016 by David S Palmer, Holly Butler, and Matthew Baker. The firm specializes in developing advanced diagnostics for the early detection of various cancers, focusing on Stage I and Stage II malignancies where timely intervention can significantly improve patient outcomes. Utilizing a combination of infrared spectroscopy and artificial intelligence, Dxcover's technology enables the detection of cancer from a simple blood sample, allowing for same-day diagnosis and patient stratification. This innovative approach aims to enhance treatment options and ultimately improve survival rates and quality of life for patients.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

ENOUGH is a company that develops and commercializes patented technology for producing mycoprotein, a meat-free food product. Its innovative process integrates production within existing bio-refineries, creating a sustainable and efficient system that produces Food, Fuel, and Feed simultaneously.

Biotangents Ltd. is a biotechnology company based in Glasgow, United Kingdom, specializing in the design and construction of biological pathways to produce desirable natural materials. Founded in 2015, Biotangents utilizes its proprietary Leapfrog Assembly platform to create complex genetic constructs from multiple DNA components. The company has developed notable technologies such as Short Sequence Randomisation and Moduleic Sensing, the latter of which focuses on modular cell-free nucleic acid detection. Biotangents is also engaged in creating a veterinary diagnostic device aimed at detecting various infectious diseases in livestock. This device utilizes isothermal amplification technology, allowing for precise molecular detection without extensive technical requirements, and can be swiftly adapted to target new pathogens. Through its innovations, Biotangents strives to mitigate the impact of infectious diseases in livestock, enabling more efficient production of animal protein.

Bio-Images Drug Delivery Ltd, based in Glasgow, United Kingdom, specializes in drug formulation and delivery systems. The company offers a comprehensive range of services tailored to meet individual client needs, including troubleshooting, formulation development, and both in vitro and in vivo testing. Bio-Images is known for its patented time release technology, OralogiK, which provides precise control over drug release timing and location, allowing for the oral delivery of single, multi-dose, or combination drugs within a timeframe of one to twelve hours after ingestion. This technology supports various dosing strategies, such as nighttime administration and multi-phased delivery, which enhance therapeutic efficacy. Additionally, the company employs gamma scintigraphy to analyze the in vivo behavior of formulations, offering insights into disintegration timing, gastric emptying, and gastrointestinal transit. Bio-Images also features a clinical division that manages all aspects of clinical study processes, from protocol development and regulatory submissions to the production of compliant clinical study reports.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Causeway Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Glasgow, United Kingdom, dedicated to developing novel microRNA therapies for musculoskeletal health. Founded in 2015, the company specializes in treating tendon injuries and disorders in both humans and horses. Its key products include EquiMiR, a treatment for equine tendinopathy that mimics natural microRNA with enhanced pharmacological properties, and TenoMiR, which restores critical microRNA levels to improve tendon strength and facilitate recovery. By targeting the molecular mechanisms underlying tendon damage and tendinopathy, Causeway Therapeutics aims to provide advanced therapeutic solutions that alleviate pain and promote faster healing for patients suffering from musculoskeletal diseases.

ENOUGH is a company that develops and commercializes patented technology for producing mycoprotein, a meat-free food product. Its innovative process integrates production within existing bio-refineries, creating a sustainable and efficient system that produces Food, Fuel, and Feed simultaneously.

Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.

EnteroBiotix develops orally available microbial therapeutics derived from human gastrointestinal tract bacteria. Its focus is preventing and treating diseases by restoring gut microbiota balance.

Lamellar Biomedical Ltd. is a biotechnology company based in Bellshill, United Kingdom, established in 2006. The company specializes in the development and commercialization of medical devices and pharmaceuticals centered around Lamellasomes, a synthetic substance that imitates the function of extra-alveolar lamellar bodies. Lamellar Biomedical's innovative products target various respiratory diseases, including cystic fibrosis, and conditions such as radiotherapy-induced xerostomia and dry eye disease. The company’s therapeutic platform leverages anti-infective properties to enhance antibiotic efficacy and protect lung tissues, particularly in complex cases like idiopathic pulmonary fibrosis. Additionally, it facilitates the intracellular delivery of genetic material for pulmonary disease treatment, aiming to provide transformative therapies for severe respiratory conditions. Lamellar Biomedical was previously known as Macrocom (964) Limited before adopting its current name in February 2007.

Synpromics Ltd. is a biotechnology company based in Edinburgh, United Kingdom, founded in 2010. The company specializes in the development and commercialization of synthetic promoters, which are crucial for controlling gene expression and regulation. Synpromics aims to enhance human health by facilitating the creation of safer and more effective cell and gene therapies. Utilizing proprietary genomics and bioinformatics, along with an intelligent data-driven design approach, Synpromics provides a multi-dimensional bioinformatics database that supports product-specific promoter design and selection. This technology empowers biological researchers and developers in the AgBio sector to innovate and improve efficacy and safety in the development of new medicines and bioprocessing applications. As of August 2019, Synpromics operates as a subsidiary of Asklepios BioPharmaceutical, Inc.

MGB Biopharma is a UK-based biopharmaceutical company developing novel anti-infective medicines. It focuses on small molecules with specific antibacterial effects, targeting resistant bacteria using its proprietary DNA Minor Groove Binders technology.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

Elasmogen Ltd is a biopharmaceutical company based in Aberdeen, United Kingdom, founded in 2014. The company specializes in discovering and developing novel therapies for inflammatory eye diseases and other autoimmune conditions. Elasmogen's primary innovation lies in its proprietary soloMER technology, which consists of small, stable proteins derived from variable new-antigen receptors (VNARs) found in sharks. These next-generation therapeutics are designed to be significantly smaller and more robust than traditional antibodies while avoiding complex patent landscapes. Elasmogen's pipeline includes various candidates targeting autoimmune-mediated inflammatory diseases, such as ELN/21 and ELN/22, as well as soloMER-drug conjugates and NDure, which enhances the plasma half-life of therapeutic molecules. The company has established strategic partnerships with Almac Discovery Ltd and Merck Inc., and it possesses a comprehensive intellectual property portfolio that includes exclusive licenses for over 20 patents across multiple jurisdictions.

TC Biopharm Limited is a clinical development company based in Edinburgh, United Kingdom, that specializes in the development, manufacturing, and commercialization of innovative cell-based products aimed at treating cancer and severe viral infections. The company’s flagship product, ImmuniCell, is an autologous therapy that expands patient-derived cells in a cleanroom environment to create treatments for various tumor types and viral infections. TC Biopharm is advancing its pipeline through Phase II/III clinical studies, focusing on conditions such as renal cell carcinoma, non-small cell lung cancer, and melanoma. The company is committed to developing safer, more effective, and durable therapies, utilizing its proprietary allogeneic gamma delta T cell platform to harness the innate immune response against malignancies and infections. Through strategic partnerships and collaborations with organizations like Medinet and bluebird bio, TC Biopharm aims to enhance its capabilities and accelerate the delivery of its therapies to patients.

Alfacyte Ltd. develops an immunoregulatory formulation for the oral treatment of food allergies based on the immunological activities of two candidate cytokines, with adjuvant-like activities. Its immunoregulatory combination therapy is used for the oral treatment of peanut allergy.

MOFgen Ltd is a pioneering company that specializes in the development and commercialization of metal-organic frameworks (MOFs) for medical and therapeutic applications. Originating as a spin-out from the University of St Andrews, MOFgen leverages patented technology developed by renowned porous material scientist Prof. Russell Morris. The company focuses on creating innovative solutions to healthcare challenges by designing and manufacturing MOFs that can be loaded with antibacterial, wound healing, and anti-thrombotic agents. These products are intended for use in coatings on medical devices, aiming to enhance patient care by reducing infection rates and minimizing the need for prolonged hospital stays. Through collaboration with various partners, MOFgen is dedicated to addressing critical issues such as healthcare-associated infections, bacterial resistance, chronic wound healing, and arterial access.

CuanTec Ltd is a Scottish biotechnology company based in Motherwell, United Kingdom, founded in 2016. The company specializes in manufacturing biodegradable and compostable plastic films specifically for the food industry, using an innovative process that extracts chitin from the waste of shellfish, particularly langoustines. By utilizing a circular economy approach, CuanTec transforms marine waste from the fisheries industry into environmentally responsible packaging solutions. Their production process is low-energy and minimizes waste, employing harmless bacteria to extract chitin, resulting in a high-quality product. CuanTec's films are not only antimicrobial but also compostable and biodegradable, addressing the pressing issue of plastic pollution and helping to extend the shelf life of fresh food while reducing food waste.

CelluComp Ltd. is a material science company based in Burntisland, United Kingdom, specializing in the development and commercialization of biobased materials derived from food processing industry waste streams. Founded in 2004, the company produces Curran, a high-performance material made from nano-cellulose fibers extracted from root vegetables. CelluComp offers a range of products, including Curran paste, slurry, and powders, which are suitable for various applications such as paints, coatings, paper, personal care, and construction materials. Its innovative offerings serve multiple industries and aim to provide environmentally sustainable alternatives by utilizing non-hydrocarbon feedstocks. The company distributes its products across several countries, including the United Kingdom, Germany, and several nations in Europe and the Middle East.

Caldan Therapeutics is a spinout from the University of Glasgow and the University of Southern Denmark focused on developing therapeutics that modulate free fatty acid receptors to address metabolic diseases, including Type 2 Diabetes, with potential applications in non-alcoholic steatohepatitis and inflammatory conditions. Building on a long-term collaboration between leading researchers, the company seeks to target multiple aspects of diabetes pathology, such as insulin secretion, insulin sensitivity, and islet cell protection, while aiming to reduce inflammatory activity in muscle, liver, and adipose tissue. The approach centers on delivering glucose-lowering effects by modulating receptor pathways implicated in diabetes and related inflammatory diseases.

Taragenyx Ltd. is an orthopedic biotechnology company based in Glasgow, United Kingdom, that specializes in developing innovative self-healing implant technologies to assist the body in its natural repair processes. Founded in 2010 and originally known as RRG Coatings Ltd., Taragenyx focuses on applications in spine, trauma, extremities, and biologics. The company is engaged in creating therapeutic implants featuring bio-passive, bio-active, and bio-regenerative coatings that incorporate active pharmaceuticals and biologics directly onto the implant surfaces. This technology enables localized release of compounds post-operatively, aiming to accelerate bone growth, enhance healing, and diminish the risks of infection and pain. Taragenyx’s products are designed to address and mitigate limb-threatening surgical complications, ultimately improving patient outcomes in orthopedic and dental procedures.

Biogelx Ltd. is a biomaterials company based in Newhouse, United Kingdom, that specializes in the development and supply of tuneable peptide hydrogels. Founded in 2012, the company focuses on creating hydrogels specifically designed for cell culture applications, including cell-based toxicity screening, cancer research, and the reduction of animal testing. These hydrogels mimic the chemical and physical properties of natural tissues, allowing researchers to study and manipulate cells within a realistic three-dimensional environment. Biogelx's patented products offer significant advantages for academic institutions, medical researchers, and pharmaceutical companies, providing a viable alternative to existing 3D cell culture solutions. The company's innovative approach aims to facilitate advancements in fundamental cell research and has potential applications in cell therapy and regenerative medicine. Biogelx's hydrogels are currently marketed in the United States, Europe, and Asia.

Clyde Biosciences is a developer of cardiac cell analysis solutions that provide human-relevant data to de-risk drug development. The company creates cell-based assays and analytics to reveal how drug compounds affect heart cells, enabling assessment of efficacy and potential cardiotoxicity in early research. Its offerings include cellOPTIQ, an optical action potential assay that measures drug effects on human cardiomyocytes, and XTENDSR, which quantifies drug-induced changes in cardiac sarcoplasmic reticulum function. By translating cellular responses into functional cardiomyocyte data, Clyde Biosciences supports pharmaceutical and biotechnology companies in identifying safety risks earlier and guiding molecule selection. Headquartered in Glasgow, United Kingdom, the company serves clients internationally and focuses on delivering human-relevant, mechanistic insights to improve the safety profile of new medicines.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.

Relitect Limited is a technology company based in Motherwell, United Kingdom, focused on developing innovative diagnostic solutions for the life sciences industry. Founded in 2014, Relitect specializes in a novel assay platform that enables label-free electrochemical detection of binding events. This proprietary technology allows for the highly sensitive analysis of proteins, small molecules, and nucleic acids, making it suitable for clinical diagnostics and research applications. By utilizing small sample volumes and a multiplexed format, Relitect's technology minimizes sample interference and eliminates the potential for cross-talk between labeled reagents, enhancing the accuracy of biomarker detection.

DestiNA Genomics Ltd. is a molecular diagnostic company based in Edinburgh, United Kingdom, and was incorporated in 2010 as a spin-out from the University of Edinburgh. The company specializes in a novel chemical-based system for the detection of nucleic acids and single nucleotide polymorphisms, distinguishing itself from existing enzymatic methods. DestiNA Genomics offers a range of reagents and probes for detecting nucleic acids and mutations, as well as probe sets and assays aimed at drug development and profiling. Its technology is particularly effective for direct detection of micro-RNAs and is being integrated into various detection platforms, including colorimetric, fluorescent, and electrochemical systems. Additionally, DestiNA has established a subsidiary in Spain, DestiNA Genomica SL, to exploit its technology in collaboration with local partners. The company is committed to advancing diagnostic capabilities in areas such as cancer biomarkers, inherited diseases, and infectious diseases.

MGB Biopharma is a UK-based biopharmaceutical company developing novel anti-infective medicines. It focuses on small molecules with specific antibacterial effects, targeting resistant bacteria using its proprietary DNA Minor Groove Binders technology.

ProFactor Pharma Limited is a biotechnology company based in Roslin, United Kingdom, that specializes in the development and commercialization of recombinant blood factors for the treatment of hemophilia. Founded in 2009, the company focuses on producing Factor VIII, a complex and unstable protein essential for blood clotting. ProFactor Pharma is committed to creating commercial and Good Manufacturing Practice (GMP) compliant cell lines that produce recombinant Factor VIII. By leveraging proprietary high-expressing cell lines and innovative manufacturing technologies, the company aims to provide healthcare institutions with affordable and effective treatment options for hemophilia, a serious genetic disorder that impairs the body’s ability to form blood clots and can lead to severe health complications.